Partnership Opportunities

Our partners positioned their companies at the forefront of the minds of leading biopharma at the 3rd Rare & Genetic Kidney Disease Drug Development Summit, dedicated to pushing the boundaries in cutting-edge rare & genetic kidney disease research and drug development using multi-omics, preclinical models, and genetic testing.

Non-stop momentum in the treatment of orphan renal diseases has enhanced understanding of disease pathophysiology and innovative clinical trial designs using surrogate endpoints, novel biomarkers, genomics, real-world evidence and more!

Partner with us to showcase your brand and capitalize on our audience of leading companies with active pipelines in rare and genetic kidney diseases.

HI-Bio, Otsuka, Purespring Therapeutics, Maze Therapeutics were amongst our other
100+ attendees in 2023 seeking partners to help them in the following areas:

Contract Research – accelerate and support preclinical and clinical R&D and position yourself as the leading CRO in orphan kidney diseases

Genetic Testing - showcase your capabilities to advance molecular diagnostics to help inform nephrologists on more personalized health care decisions for their patients

Novel Biomarkers – communicate your capabilities to enhance the development and validation of biomarkers of progression

Preclinical Services – explore your expertise in preclinical models and study tools for IgAN, FSGS, Alport Syndrome, PKD and others

Why Partner?

Educate the Industry: Secure a speaking position to explain how your solutions can directly support industry challenges in a room full of potential clients

Meet Senior Decision Makers: Our meeting will unite CEOs, COOs, VPs, Directors, and Presidents creating a niche environment so you can network directly with the most senior decision makers in the industry

Showcase Your Products: Bypass the crowds in large trade shows and assert your authority by displaying your services with our targeted exhibition space

Gain Brand Visibility: Broaden your company’s exposure with 100+ dedicated delegates Eli Lilly, Janssen, FDA, Novo Nordisk, Travere Therapeutics, Chinook Therapeutics, and many more in attendance

Who Was there?

audience summary

*Based on the attendance of 2nd Rare and Genetic Kidney Disease Drug Development Summit